Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Conference item |
Idioma: | English |
Publicado: |
Oxford University Press
2019
|